Themis Medicare growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
−15.6%+6.2%+7.7%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−99.2%−4.8%−23.6%
−125.4%−0.4%−31.1%
−96.2%−31.5%−23.5%
−96.3%−31.5%−92.3%
+1.7%+3.8%+10.2%
−1.0%+6.6%+11.3%
−109.4%+139.9%−10.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

THEMISMED₹97.52

Themis Medicare Limited

· Pharma & Health
₹ CrorePeersLINCOLNBAJAJHCARESIGACHIWANBURYAMRUTANJANAHCLANUHPHRMcap ₹898 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+7.7+6.2-15.6—
EBITDA Growth—-23.6-4.8-99.2—
EBIT Growth—-31.1-0.4-125.4—
Net Income Growth—-23.5-31.5-96.2—
EPS Growth—-92.3-31.5-96.3—
Total Assets Growth—+10.2+3.8+1.7—
Total Equity Growth—+11.3+6.6-1.0—
Cash from Operations Growth—-10.1+139.9-109.4—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.